Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Study Parts A and B:~-Cirrhosis of alcohol aetiology according to physician's assessment prior to screening.~Part A:~-Cirrhosis with clinical and/or endoscopic evidence of portal hypertension (e.g. oesophageal varices).~Part B:~* Cirrhosis with TIPSS in situ and PPG\>5mmHg.~* Fully functioning TIPSS without variceal filling as confirmed by portography.~Exclusion Criteria:~Study Parts A and B:~* Use of any drug to treat portal hypertension (e.g. vasodilators such as non-selective beta blockers or nitrates) within 1 month prior to screening.~* Decompensated cirrhosis (Child-Pugh score \>9 points, and/or ascites requiring diuretics, and/or hepatic encephalopathy) at visit 1.~* Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.~Part A:~* BMI (weight\[kg\] / height\[m\^2\]) \> 40 kg/m\^2.~* Any contraindication to having an MRI scan~Part B:~-Contraindication to catheterization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Terlipressin acetate (Type: EXPERIMENTAL): Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
- Part A: Serelaxin (RLX030) (Type: EXPERIMENTAL): Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
- Part B Serelaxin (RLX030) (Type: EXPERIMENTAL): The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.

Based on this trial design, predict the completion outcome and termination type (if applicable).